Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In-hospital dapagliflozin initiation for stabilized acute heart failure
2022-001262-35Phase 3Active
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Time to first occurrence of cardiovascular death or worsening heart failure. Started Jul 2022; status: active.
02
Drugs
dapagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2022-001262-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001262-35.